Clinical study of administration of alpha-GalactosylCeramide-pulsed DCs by bronchoscopy in patients with either advanced or recurrent non-small cell lung cancer (NSCLC)

Clinical study of administration of alpha-GalactosylCeramide-pulsed DCs by bronchoscopy in patients with either advanced or recurrent non-small cell lung cancer (NSCLC) - Clinical study of administration of alpha-GalactosylCeramide-pulsed DCs by the bronchoscopy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005208

Enrollment

Registered

2011-03-08

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Intratumoral or intranodal administrations of alpha-GalactocylCeramide pulsed DCs by bronchoscopy are performed on day 7 and 14 after the entry.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with either advanced or recurrent non-small cell lung cancer, who have received chemotherapy or radiotherapy. Patients who have measurable disease in the lung and have lymph node over 5mm diameter. Patients whose life-expectancy is more than 6 months; Performance status 0-2; Normal bone marrow, liver and renal functions; NKT cells are detected at least 10 cells in 1 ml of peripheral blood.

Exclusion criteria

Exclusion criteria: Patients who have: uncontrolled diabetes mellitus, pulmonary fibrosis, and/or infection; synchronous multiple cancer; a history of hepatitis; a positive response for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV), or human T-lymphotrophic virus antibodies; serious cardiac diseases; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to practice in this study by principle investigator

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
The clinical effects and immunological responses	—

Countries

Japan

Contacts

Public ContactShinichiro Motohashi

raduate School of Medicine, Chiba University Department of immunology

043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026